论文部分内容阅读
急性淋巴母细胞性白血病共同抗原(CommonAcute lymphoblastic leukemia antigen,CALLA)是一种分子量为10万道尔顿的细胞表面糖蛋白。临床急性白血病患者的白血病细胞上这种抗原的存在对疾病的诊断是有价值的。由于CALLA 抗原的分布限于白血病细胞,CALLA 抗原特异的单克隆抗体被认为可用于白血病的体内血清学治疗。虽然这些血清疗法在临床上未能取得显著疗效,但是它们也没有大的临床付作用.实验发现,白血病细胞接触CALLA 抗原特异性
Common acute lymphoblastic leukemia antigen (CALLA) is a cell surface glycoprotein with a molecular weight of 100,000 Daltons. The presence of this antigen on leukemia cells in clinically acute leukemia patients is valuable for the diagnosis of the disease. Since the distribution of CALLA antigens is restricted to leukemia cells, monoclonal antibodies specific for CALLA antigens are considered useful for in vivo serological treatment of leukemia. Although these serum therapies failed to achieve clinically significant results, they also did not have a large clinical side effect. It was found that leukemia cells were specifically exposed to CALLA antigens.